Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Two-pronged approach to anti-inflammatory therapy through the modulation of the arachidonic acid cascade.

Sala A, Proschak E, Steinhilber D, Rovati GE.

Biochem Pharmacol. 2018 Dec;158:161-173. doi: 10.1016/j.bcp.2018.10.007. Epub 2018 Oct 11. Review.

PMID:
30315753
2.

Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology.

Schierle S, Flauaus C, Heitel P, Willems S, Schmidt J, Kaiser A, Weizel L, Goebel T, Kahnt AS, Geisslinger G, Steinhilber D, Wurglics M, Rovati GE, Schmidtko A, Proschak E, Merk D.

J Med Chem. 2018 Jul 12;61(13):5758-5764. doi: 10.1021/acs.jmedchem.8b00458. Epub 2018 Jun 22.

PMID:
29878767
3.

Nonsteroidal Anti-Inflammatory Drugs: Exploiting Bivalent COXIB/ TP Antagonists for the Control of Cardiovascular Risk.

Carnevali S, Buccellati C, Bolego C, Bertinaria M, Rovati GE, Sala A.

Curr Med Chem. 2017;24(30):3218-3230. doi: 10.2174/0929867324666170602083428. Review.

PMID:
28571535
4.

The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.

Hoxha M, Rovati GE, Cavanillas AB.

Eur J Clin Pharmacol. 2017 Jul;73(7):799-809. doi: 10.1007/s00228-017-2242-2. Epub 2017 Apr 4. Review.

PMID:
28374082
5.

The DRY motif and the four corners of the cubic ternary complex model.

Rovati GE, Capra V, Shaw VS, Malik RU, Sivaramakrishnan S, Neubig RR.

Cell Signal. 2017 Jul;35:16-23. doi: 10.1016/j.cellsig.2017.03.020. Epub 2017 Mar 24. Review.

PMID:
28347873
6.

Cysteinyl Leukotrienes Pathway Genes, Atopic Asthma and Drug Response: From Population Isolates to Large Genome-Wide Association Studies.

Thompson MD, Capra V, Clunes MT, Rovati GE, Stankova J, Maj MC, Duffy DL.

Front Pharmacol. 2016 Dec 1;7:299. eCollection 2016. Review.

7.

Impaired thromboxane receptor dimerization reduces signaling efficiency: A potential mechanism for reduced platelet function in vivo.

Capra V, Mauri M, Guzzi F, Busnelli M, Accomazzo MR, Gaussem P, Nisar SP, Mundell SJ, Parenti M, Rovati GE.

Biochem Pharmacol. 2017 Jan 15;124:43-56. doi: 10.1016/j.bcp.2016.11.010. Epub 2016 Nov 11.

8.

Design and Characterization of Superpotent Bivalent Ligands Targeting Oxytocin Receptor Dimers via a Channel-Like Structure.

Busnelli M, Kleinau G, Muttenthaler M, Stoev S, Manning M, Bibic L, Howell LA, McCormick PJ, Di Lascio S, Braida D, Sala M, Rovati GE, Bellini T, Chini B.

J Med Chem. 2016 Aug 11;59(15):7152-66. doi: 10.1021/acs.jmedchem.6b00564. Epub 2016 Jul 28.

PMID:
27420737
9.

In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition.

Hoxha M, Buccellati C, Capra V, Garella D, Cena C, Rolando B, Fruttero R, Carnevali S, Sala A, Rovati GE, Bertinaria M.

Pharmacol Res. 2016 Jan;103:132-43. doi: 10.1016/j.phrs.2015.11.012. Epub 2015 Nov 24.

10.

A potential role of PUFAs and COXIBs in cancer chemoprevention.

Vara-Messler M, Buccellati C, Pustina L, Folco G, Rovati GE, Hoxha M.

Prostaglandins Other Lipid Mediat. 2015 Jul;120:97-102. doi: 10.1016/j.prostaglandins.2015.04.003. Epub 2015 Apr 20. Review.

PMID:
25908304
11.

Transcellular biosynthesis of eicosanoid lipid mediators.

Capra V, Rovati GE, Mangano P, Buccellati C, Murphy RC, Sala A.

Biochim Biophys Acta. 2015 Apr;1851(4):377-82. doi: 10.1016/j.bbalip.2014.09.002. Epub 2014 Sep 16. Review.

PMID:
25218301
12.

Pharmacogenetics of the G protein-coupled receptors.

Thompson MD, Cole DE, Capra V, Siminovitch KA, Rovati GE, Burnham WM, Rana BK.

Methods Mol Biol. 2014;1175:189-242. doi: 10.1007/978-1-4939-0956-8_9. Review.

PMID:
25150871
13.

Functional characterization of E. coli LptC: interaction with LPS and a synthetic ligand.

Sestito SE, Sperandeo P, Santambrogio C, Ciaramelli C, Calabrese V, Rovati GE, Zambelloni L, Grandori R, Polissi A, Peri F.

Chembiochem. 2014 Mar 21;15(5):734-42.

PMID:
24677607
14.

The DRY motif at work: the P2Y12 receptor case.

Rovati GE, Capra V.

J Thromb Haemost. 2014 May;12(5):713-5. doi: 10.1111/jth.12543. No abstract available.

15.

Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7.

Bäck M, Powell WS, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE.

Br J Pharmacol. 2014 Aug;171(15):3551-74. doi: 10.1111/bph.12665. Epub 2014 Jul 12. Review.

16.

Rosuvastatin inhibits human airway smooth muscle cells mitogenic response to eicosanoid contractile agents.

Capra V, Rovati GE.

Pulm Pharmacol Ther. 2014 Feb;27(1):10-6. doi: 10.1016/j.pupt.2013.06.005. Epub 2013 Jun 24.

PMID:
23806820
17.

Full and partial agonists of thromboxane prostanoid receptor unveil fine tuning of receptor superactive conformation and G protein activation.

Capra V, Busnelli M, Perenna A, Ambrosio M, Accomazzo MR, Galés C, Chini B, Rovati GE.

PLoS One. 2013;8(3):e60475. doi: 10.1371/journal.pone.0060475. Epub 2013 Mar 28.

18.

Designing multitarget anti-inflammatory agents: chemical modulation of the lumiracoxib structure toward dual thromboxane antagonists-COX-2 inhibitors.

Bertinaria M, Shaikh MA, Buccellati C, Cena C, Rolando B, Lazzarato L, Fruttero R, Gasco A, Hoxha M, Capra V, Sala A, Rovati GE.

ChemMedChem. 2012 Sep;7(9):1647-60. doi: 10.1002/cmdc.201200272. Epub 2012 Aug 2. Erratum in: ChemMedChem. 2012 Dec;7(12):2054.

19.

Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke.

Capra V, Bäck M, Barbieri SS, Camera M, Tremoli E, Rovati GE.

Med Res Rev. 2013 Mar;33(2):364-438. doi: 10.1002/med.21251. Epub 2012 Mar 20. Review.

PMID:
22434418
20.

International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions.

Bäck M, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE.

Pharmacol Rev. 2011 Sep;63(3):539-84. doi: 10.1124/pr.110.004184. Review.

PMID:
21771892
21.

Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT2 receptor.

Carnini C, Accomazzo MR, Borroni E, Vitellaro-Zuccarello L, Durand T, Folco G, Rovati GE, Capra V, Sala A.

FASEB J. 2011 Oct;25(10):3519-28. doi: 10.1096/fj.10-177030. Epub 2011 Jul 13.

PMID:
21753081
22.

Light on the structure of thromboxane A₂receptor heterodimers.

Fanelli F, Mauri M, Capra V, Raimondi F, Guzzi F, Ambrosio M, Rovati GE, Parenti M.

Cell Mol Life Sci. 2011 Sep;68(18):3109-20. doi: 10.1007/s00018-010-0615-0. Epub 2011 Jan 7.

PMID:
21213014
23.

Superactive mutants of thromboxane prostanoid receptor: functional and computational analysis of an active form alternative to constitutively active mutants.

Ambrosio M, Fanelli F, Brocchetti S, Raimondi F, Mauri M, Rovati GE, Capra V.

Cell Mol Life Sci. 2010 Sep;67(17):2979-89. doi: 10.1007/s00018-010-0368-9. Epub 2010 Apr 11.

PMID:
20383734
24.

Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk.

Rovati GE, Sala A, Capra V, Dahlén SE, Folco G.

Trends Pharmacol Sci. 2010 Mar;31(3):102-7. doi: 10.1016/j.tips.2009.11.007. Epub 2010 Feb 1.

PMID:
20117851
25.

A role for inflammatory mediators in heterologous desensitization of CysLT1 receptor in human monocytes.

Capra V, Accomazzo MR, Gardoni F, Barbieri S, Rovati GE.

J Lipid Res. 2010 May;51(5):1075-84. doi: 10.1194/jlr.M003236. Epub 2009 Nov 15.

26.

Heterotrimeric G proteins demonstrate differential sensitivity to beta-arrestin dependent desensitization.

Innamorati G, Giannone F, Guzzi F, Rovati GE, Accomazzo MR, Chini B, Bianchi E, Schiaffino MV, Tridente G, Parenti M.

Cell Signal. 2009 Jul;21(7):1135-42. doi: 10.1016/j.cellsig.2009.03.002. Epub 2009 Mar 9.

PMID:
19275934
27.

Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappaB p65-associated histone acetyltransferase activity.

Tahan F, Jazrawi E, Moodley T, Rovati GE, Adcock IM.

Clin Exp Allergy. 2008 May;38(5):805-11. doi: 10.1111/j.1365-2222.2008.02963.x. Epub 2008 Mar 5.

PMID:
18325031
28.

Antagonism of thromboxane receptors by diclofenac and lumiracoxib.

Selg E, Buccellati C, Andersson M, Rovati GE, Ezinga M, Sala A, Larsson AK, Ambrosio M, Låstbom L, Capra V, Dahlén B, Ryrfeldt A, Folco GC, Dahlén SE.

Br J Pharmacol. 2007 Dec;152(8):1185-95. Epub 2007 Oct 29. Erratum in: Br J Pharmacol. 2008 Apr;153(8):1763. Ambrosio, E [corrected to Ambrosio, M].

29.

Cysteinyl-leukotriene receptors and cellular signals.

Rovati GE, Capra V.

ScientificWorldJournal. 2007 Sep 1;7:1375-92. Review.

30.

A functional G300S variant of the cysteinyl leukotriene 1 receptor is associated with atopy in a Tristan da Cunha isolate.

Thompson MD, Capra V, Takasaki J, Maresca G, Rovati GE, Slutsky AS, Lilly C, Zamel N, McIntyre Burnham W, Cole DE, Siminovitch KA.

Pharmacogenet Genomics. 2007 Jul;17(7):539-49.

PMID:
17558309
31.

The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state.

Rovati GE, Capra V, Neubig RR.

Mol Pharmacol. 2007 Apr;71(4):959-64. Epub 2006 Dec 27. Review.

PMID:
17192495
32.

Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities.

Capra V, Ambrosio M, Riccioni G, Rovati GE.

Curr Med Chem. 2006;13(26):3213-26. Review.

PMID:
17168708
33.

G-protein-coupled receptors and asthma endophenotypes: the cysteinyl leukotriene system in perspective.

Thompson MD, Takasaki J, Capra V, Rovati GE, Siminovitch KA, Burnham WM, Hudson TJ, Bossé Y, Cole DE.

Mol Diagn Ther. 2006;10(6):353-66. Review.

PMID:
17154652
34.

The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor.

Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D, Ferrario S, Parravicini C, Capra V, Gelosa P, Guerrini U, Belcredito S, Cimino M, Sironi L, Tremoli E, Rovati GE, Martini C, Abbracchio MP.

EMBO J. 2006 Oct 4;25(19):4615-27. Epub 2006 Sep 21.

35.

The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo.

Chiang N, Serhan CN, Dahlén SE, Drazen JM, Hay DW, Rovati GE, Shimizu T, Yokomizo T, Brink C.

Pharmacol Rev. 2006 Sep;58(3):463-87. Review.

PMID:
16968948
36.

Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends.

Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE.

Med Res Rev. 2007 Jul;27(4):469-527. Review.

PMID:
16894531
37.

Cysteinyl-leukotrienes in the regulation of beta2-adrenoceptor function: an in vitro model of asthma.

Rovati GE, Baroffio M, Citro S, Brichetto L, Ravasi S, Milanese M, Crimi E, Brusasco V.

Respir Res. 2006 Jul 28;7:103.

39.
40.

CysLT1 receptor is a target for extracellular nucleotide-induced heterologous desensitization: a possible feedback mechanism in inflammation.

Capra V, Ravasi S, Accomazzo MR, Citro S, Grimoldi M, Abbracchio MP, Rovati GE.

J Cell Sci. 2005 Dec 1;118(Pt 23):5625-36.

41.

CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors.

Mamedova L, Capra V, Accomazzo MR, Gao ZG, Ferrario S, Fumagalli M, Abbracchio MP, Rovati GE, Jacobson KA.

Biochem Pharmacol. 2005 Dec 19;71(1-2):115-25. Epub 2005 Nov 8.

42.

Thromboxane prostanoid receptor signals through Gi protein to rapidly activate extracellular signal-regulated kinase in human airways.

Citro S, Ravasi S, Rovati GE, Capra V.

Am J Respir Cell Mol Biol. 2005 Apr;32(4):326-33. Epub 2004 Dec 30.

PMID:
15626772
43.

Age-related decline in RACK-1 expression in human leukocytes is correlated to plasma levels of dehydroepiandrosterone.

Corsini E, Racchi M, Sinforiani E, Lucchi L, Viviani B, Rovati GE, Govoni S, Galli CL, Marinovich M.

J Leukoc Biol. 2005 Feb;77(2):247-56. Epub 2004 Nov 17.

44.

Leukotriene modifiers in asthma management.

Capra V, Rovati GE.

IDrugs. 2004 Jul;7(7):659-66. Review.

PMID:
15243868
45.

Mutational analysis of the highly conserved ERY motif of the thromboxane A2 receptor: alternative role in G protein-coupled receptor signaling.

Capra V, Veltri A, Foglia C, Crimaldi L, Habib A, Parenti M, Rovati GE.

Mol Pharmacol. 2004 Oct;66(4):880-9. Epub 2004 Jun 30.

PMID:
15229298
46.

CysLT1 signal transduction in differentiated U937 cells involves the activation of the small GTP-binding protein Ras.

Capra V, Ravasi S, Accomazzo MR, Parenti M, Rovati GE.

Biochem Pharmacol. 2004 Apr 15;67(8):1569-77.

PMID:
15041474
47.

International Union of Pharmacology XLIV. Nomenclature for the oxoeicosanoid receptor.

Brink C, Dahlén SE, Drazen J, Evans JF, Hay DW, Rovati GE, Serhan CN, Shimizu T, Yokomizo T.

Pharmacol Rev. 2004 Mar;56(1):149-57. Review.

PMID:
15001665
48.

Involvement of prenylated proteins in calcium signaling induced by LTD4 in differentiated U937 cells.

Capra V, Accomazzo MR, Ravasi S, Parenti M, Macchia M, Nicosia S, Rovati GE.

Prostaglandins Other Lipid Mediat. 2003 Jul;71(3-4):235-51.

PMID:
14518564
49.

Thromboxane prostanoid receptor in human airway smooth muscle cells: a relevant role in proliferation.

Capra V, Habib A, Accomazzo MR, Ravasi S, Citro S, Levy-Toledano S, Nicosia S, Rovati GE.

Eur J Pharmacol. 2003 Aug 8;474(2-3):149-59.

PMID:
12921856
50.

Developmental expression of heteromeric nicotinic receptor subtypes in chick retina.

Vailati S, Moretti M, Longhi R, Rovati GE, Clementi F, Gotti C.

Mol Pharmacol. 2003 Jun;63(6):1329-37.

PMID:
12761343

Supplemental Content

Loading ...
Support Center